<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237510</url>
  </required_header>
  <id_info>
    <org_study_id>05U.84</org_study_id>
    <nct_id>NCT00237510</nct_id>
  </id_info>
  <brief_title>Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating</brief_title>
  <official_title>A Pilot Study of the Efficacy and Tolerability of Terazosin for the Treatment of Antidepressant-Induced Excessive Sweating</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is based on the hypothesis that terazosin, a blocker of alpha-1 receptors, will be&#xD;
      effective in reducing excessive sweating caused by antidepressant treatment, and will have&#xD;
      minimal adverse effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sweating is a common and bothersome side effect of treatment with antidepressants. Most or&#xD;
      all antidepressants have been clearly shown to cause excessive sweating. It is unclear to&#xD;
      what extent excessive sweating caused by antidepressants becomes less or goes away with time.&#xD;
      In many instances, it continues to be a problem even after 6 or more months on the&#xD;
      antidepressant.&#xD;
&#xD;
      There is no generally accepted treatment for excessive sweating. This study has been designed&#xD;
      to study whether terazosin is effective in reducing antidepressant-induced sweating, and&#xD;
      whether it is well-tolerated and acceptable to patients. In addition, secondary objectives of&#xD;
      this study are to determine the time taken for patients to respond to terazosin, the usual&#xD;
      doses needed for improvement, and the extent of reduction in sweating. This information will&#xD;
      not only help doctors in using terazosin for this purpose in their patients, but will help in&#xD;
      designing further studies of this treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To study whether terazosin 1 to 5 mg/ day is effective in reducing antidepressant-induced sweating</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine if terazosin is tolerated and acceptable to patients as a potential treatment for antidepressant-induced sweating</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the time-course of response, the dose-response relationship, and the magnitude of effect of treatment of antidepressant-induced sweating to assist in designing a subsequent double-blind, placebo-controlled study of this treatment.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Antidepressant Induced Excessive Sweating</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terazosin</intervention_name>
    <other_name>Hytrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of a Depressive disorder (Diagnostic and Statistical Manual of&#xD;
             Mental Disorders - IV-TR)&#xD;
&#xD;
          -  Presence of excessive sweating by self-report&#xD;
&#xD;
          -  The excessive sweating started after initiation of an antidepressant and, if treatment&#xD;
             with the antidepressant was interrupted, did not persist for more than 4 weeks during&#xD;
             that interruption&#xD;
&#xD;
          -  Treatment with the antidepressant is deemed to be clinically necessary due to&#xD;
             substantial benefit from this antidepressant, and failure to respond to or tolerate an&#xD;
             alternative&#xD;
&#xD;
          -  Excessive sweating has persisted for at least 4 weeks prior to baseline assessment&#xD;
&#xD;
          -  The excessive sweating is rated by the patient as at least moderately bothersome.&#xD;
&#xD;
          -  Episodes of excessive sweating occur at least twice a week for last 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of another known disease that could potentially cause excessive sweating&#xD;
&#xD;
          -  Failure to respond to antiadrenergic (reducing activity of the sympathetic nervous&#xD;
             system) treatment in the past&#xD;
&#xD;
          -  Blood pressure less than 110 mm Hg systolic at the screening or baseline visits&#xD;
&#xD;
          -  Orthostatic hypotension by history or on assessment at the screening or baseline&#xD;
             visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes).&#xD;
&#xD;
          -  Current antihypertensive treatment&#xD;
&#xD;
          -  History of significant cardiac disease, including coronary artery disease&#xD;
&#xD;
          -  Current use of phosphodiesterase type 5 inhibitors: sildenafil (Viagraâ„¢), tadalafil&#xD;
             (CialisTM), or vardenafil (LevitraTM)&#xD;
&#xD;
          -  History of priapism (persistent and painful erection)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajnish Mago, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University Department of Psychiatry and Human Behavior</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Department of Psychiatry and Human Behavior</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>October 11, 2005</study_first_submitted>
  <study_first_submitted_qc>October 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antidepressant induced excessive sweating</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

